AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings
Irmina Olejniczak‐Staruch(Centrum Medyczne iMed24), Aleksandra Lesiak(Medical University of Lodz), Witold Owczarek(Wojskowy Instytut Medycyny Lotniczej), Igor Bednarski(Medical University of Lodz), Adam Reich(Rzeszów University of Technology), Marzena Kraska-Gacka(Medical University of Lodz), Justyna Ceryn(Medical University of Lodz), Małgorzata Skibińska(Medical University of Lodz), Anna Woźniacka(National Institute of Oncology), Joanna Sieniawska, Marcin Noweta(Medical University of Lodz), Janusz Śmigielski(State University of Applied Sciences in Konin), Magdalena Ciążyńska(Unknown), Joanna Narbutt(ENT and Allergy), Michał Waszczykowski(Medical University of Lodz)
Cited by 19
Related Papers
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
|Acta Dermato Venereologica|2012|579
Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
|Acta Dermato Venereologica|2012|502